Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 12/20 | 0.67 |
| ▸ | THRB | P10828 | 12/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6658204 | 0.94 | THRA (0.59) | THRATHRBMAPT | |
| SCHEMBL7061490 | 0.92 | THRA (0.56) | THRATHRB | |
| SCHEMBL7062138 | 0.91 | THRA (0.55) | THRATHRBMAPT | |
| SCHEMBL6660318 | 0.90 | THRA (0.66) | THRATHRBMAPT | |
| SCHEMBL1642407 | 0.89 | THRA (0.58) | THRATHRB | |
| SCHEMBL7063019 | 0.89 | THRA (0.55) | THRATHRB | |
| SCHEMBL6742192 | 0.88 | THRA (0.52) | THRATHRB | |
| SCHEMBL6735846 | 0.88 | THRA (0.53) | THRATHRB | |
| SCHEMBL6740331 | 0.88 | THRA (0.52) | THRATHRB | |
| SCHEMBL7061428 | 0.86 | THRA (0.50) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1157001-B1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2004-08-04 | — | — | EP | claimed |
| US-6689896-B2 | AMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2004-02-10 | — | — | US | claimed |
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2003-06-19 | — | — | US | claimed |
| US-6545018-B2 | Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis | PFIZER INC. | 2003-04-08 | — | — | US | claimed |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2002-04-25 | — | — | US | claimed |
| WO-2002032408-A2 | COMBINATIONS OF A THYROMIMETIC COMPOUND AND A STATIN | NOVARTIS AG (CH) | 2002-04-25 | — | — | WO | claimed |
| US-20020045751-A1 | Thyromimetic organic compounds | NOVARTIS AG (CH) | 2002-04-18 | — | — | US | claimed |
| EP-1157001-A1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | claimed |
| WO-2000051971-A1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2000-09-08 | — | — | WO | claimed |
| US-6790978-B2 | 4-HYDROXY-3-ARYLSULFONYL, 3-AMINOSULFONYL OR 3-AMINOCARBONYL-PHENOXYANILINOCARBONYL-OPTIONAL ALKYLENE-CARBOXYLIC ACID OR CARBONYL-5-TETRAZOLES | NOVARTIS AG (CH) | 2004-09-14 | — | — | US | disclosed |
| US-6689896-B2 | AMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2004-02-10 | — | — | US | disclosed |
| US-6599942-B1 | Method of lowering LDL cholesterol and Lipoprotein a levels in mammals using such compounds | NOVARTIS AG (CH) | 2003-07-29 | — | — | US | disclosed |
| US-20020107390-A1 | Thyromimetic organic compounds | KUKKOLA PAIVI J (US) | 2002-08-08 | — | — | US | disclosed |
| US-20020045751-A1 | Thyromimetic organic compounds | NOVARTIS AG (CH) | 2002-04-18 | — | — | US | disclosed |
| EP-1165502-A1 | DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058279-A1 | DIARYL DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | OXER1, THRA, TSHR | THRA 2/4885THRB 4/4885MAPT 2992/4885 |
| US-20020045751-A1 | Thyromimetic organic compounds | TPO, THRA, LPO | THRA 2/4885THRB 7/4885MAPT 3417/4885 |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | OXER1, THRA, OXGR1 | THRA 2/4885THRB 4/4885MAPT 2875/4885 |
| US-20020107390-A1 | Thyromimetic organic compounds | TSHR, NR1H3, NR1H2 | THRA 4/4885THRB 5/4885MAPT 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.